TTrialPathMatch Me to Trials
← Back to trials
RecruitingPost-partum Depression

Post-partum Depression: an Integrated Molecular-pharmaco-imaging Study

Eligible age

18–40 yrs

Accepts

Women

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Post-partum depression (PPD) is a prevalent subtype of major depressive disorder that causes a significant distress to the woman and substantial impact on the whole family. Many studies implicate the glutamatergic system in pathological processes relevant to PPD disorders. There is evidence that cell adhesion molecules (CAMs) play a key role in how glutamatergic circuits wire up during development and how glutamatergic synapses, once formed, operate. However, it is unclear how dysregulation in diverse CAMs alter glutamatergic circuitries responsible for emotional and social behavior. Here, the investigators propose to evaluate the molecular and neurobiological underpinnings of PPD focusing on CAMs at glutamatergic synapses by using an integrated approach from mouse models to human patients. Moreover, the investigators will also perform a pilot study to investigate the impact of selective antidepressants, known to be linked to CAMs, in both human and mice.

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

You may qualify if…

  • ✓ Age between 18 and 40 years;
  • ✓ female gender;
  • ✓ PPD diagnosed by DSM-5 structured clinical interview support (SCID-5) by trained medical personnel;
  • ✓ comorbidity with metabolic syndrome, which can lead to brain damage and cognitive flaws;
  • ✓ need to start citalopram therapy for clinical needs (and therefore independent of study participation) or already on therapy for no more than two weeks;
  • ✓ moderate to severe depression according to the 17-item HAM-D (score 14-24);
  • ✓ absence of disabling medical and/or neurological conditions, including heart attacks, brain injuries, neurodegenerative diseases, head trauma with loss of consciousness for more than 30 minutes;
  • ✓ Absence of concomitant psychiatric therapies (antidepressants, antipsychotics of the first and second generation and mood stabilizers);

You may not qualify if…

  • ✕ age below 18 years or above 40 years;
  • ✕ diagnosis different from PPD based on SCID-5;
  • ✕ absence of metabolic syndrome;
  • ✕ low depression according to the 17-item HAM-D (score less than 14);
  • ✕ presence of disabling medical and/or neurological conditions, including heart attacks, brain injuries, neurodegenerative diseases, head trauma with loss of consciousness for more than 30 minutes;
  • ✕ presence of concomitant drug therapies (antidepressants, first- and second-generation antipsychotics and mood stabilizers);
  • ✕ presence of contraindications for MRI scanning;
  • ✕ presence of contraindications for citalopram;

Where it's recruiting

Source: ClinicalTrials.gov · NCT06131255 · last updated 2026-11-12

Post-partum Depression: an Integrated Molecular-pharmaco-imaging Study · TrialPath